NCT06701305CompletedPhase 1
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen
Source: ClinicalTrials.gov · Last updated 26 Feb 2025
Brief summary (registry, in English)
The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses (Part 2). In addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (Part 2 only).
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 20 Nov 2024
- Start date
- 13 Jun 2024
- Primary completion date
- 18 Feb 2025
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Obesity
- NCT number
- NCT06701305
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- From 13 Jun 2024 to the primary completion date, 18 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of clinically significant endocrine, gastrointestinal (GI), cardiovascular (CV), hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- History of cancer (malignancy)
- Positive test(s) for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or Human immunodeficiency virus (HIV)
Other
- The main exclusion criteria include but are not limited to the following:
Who the study is looking for
- The main inclusion criteria include but are not limited to the following:
- Is in good health
- Has body mass index (BMI) between 29 kg/m\^2 and 38 kg/m\^2
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| QPS-MRA, LLC ( Site 0001) Coordinator of this site? Confirm its status | South Miami | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.